Hospital Acute Care - Aggrastat

Aggrastat® (tirofiban hydrochloride) is a reversible GP IIb/IIIa inhibitor (an intravenous anti-platelet drug) for use in patients with Acute Coronary Syndrome. For full prescribing information, including further details about indications, contraindications, warnings and precautions, please consult the Aggrastat Product Monograph.

Download Product Monograph
ENGLISH | FRENCH

Hospital Acute Care - Brinavess

Brinavess® (vernakalant hydrochloride) is for the rapid conversion of recent onset atrial fibriallation (“AF”) to sinus rhythm in adults, for non-surgery patients with AF of seven days or less and for use in post-cardiac surgery patients with AF of three days or less. Brinavess is NOT recommended for conversion of atrial flutter (AFL) to sinus rhythm.

Download Product Monograph
ENGLISH | FRENCH

Download Pre-Infusion Checklist
ENGLISH & FRENCH

Hospital Acute Care - Xydalba

Xydalba (dalbavancin for injection) is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus) and Enterococcus faecalis (vancomycin susceptible strains).

Download Product Monograph
ENGLISH | FRENCH